全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Modulation of Microglia Cell Phenotype by Semi-Allogeneic Cancer Vaccines

DOI: 10.4236/jct.2026.172010, PP. 90-104

Keywords: Glioblastoma, Immunotherapy, Cancer, Vaccine, T-Cell, Microglia

Full-Text   Cite this paper   Add to My Lib

Abstract:

Glioblastoma multiforme (GBM) is the deadliest brain tumor and is one of a group of tumors referred to as gliomas. GBMs make up approximately 15% of all primary brain tumors. Even with the standard therapies of surgical resection with radiation and chemotherapy, the prognosis for patients is poor. Semiallogeneic vaccines (SAV) have demonstrated efficacy in animal models of GBM; however, the mechanisms associated with this effect are not well understood. In the current study, we examined the potential impact of SAV on the regulation of microglia in the brain. The impact of interferon-γ (IFN-γ) and vaccine mediated pathways was investigated for their effect on microglia and the modulation of phenotypic expression. In vitro studies revealed that IFN-γ directly and SAV treatment of dendritic cells and T-cells can mediate the production of interferon-γ that can allow for the induction of M1 microglia to facilitate tumor regression. In vitro studies revealed that phenotypic modulation of microglia by interferon-γ either by direct stimulation or mediated through T-cells contributes to the therapeutic effect on GBMs.

References

[1]  Ostrom, Q.T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., et al. (2013) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro-Oncology, 15, ii1-ii56.
https://doi.org/10.1093/neuonc/not151
[2]  Brooks, L.J. and Parrinello, S. (2017) Vascular Regulation of Glioma Stem-Like Cells: A Balancing Act. Current Opinion in Neurobiology, 47, 8-15.
https://doi.org/10.1016/j.conb.2017.06.008
[3]  Lakin, N., Rulach, R., Nowicki, S. and Kurian, K.M. (2017) Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma. Frontiers in Oncology, 7, Article 141.
https://doi.org/10.3389/fonc.2017.00141
[4]  Nørøxe, D.S., Poulsen, H.S. and Lassen, U. (2017) Hallmarks of Glioblastoma: A Systematic Review. ESMO Open, 1, e000144.
https://doi.org/10.1136/esmoopen-2016-000144
[5]  Ciregia, F., Urbani, A. and Palmisano, G. (2017) Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 10, Article 276.
https://doi.org/10.3389/fnmol.2017.00276
[6]  Reznik, E., Smith, A.W., Taube, S., Mann, J., Yondorf, M.Z., Parashar, B., et al. (2018) Radiation and Immunotherapy in High-Grade Gliomas. American Journal of Clinical Oncology, 41, 197-212.
https://doi.org/10.1097/coc.0000000000000406
[7]  http://www.cancer.org/cancer/braincnstumorsinadults/detailedguide/brain-and-spinal-cord-tumors-in-adults-survival-rates
[8]  Arrigo, R.T., Boakye, M. and Skirboll, S.L. (2012) Patterns of Care and Survival for Glioblastoma Patients in the Veterans Population. Journal of Neuro-Oncology, 106, 627-635.
https://doi.org/10.1007/s11060-011-0702-6
[9]  Fabre, J.W. (2001) The Allogeneic Response and Tumor Immunity. Nature Medicine, 7, 649-652.
https://doi.org/10.1038/89008
[10]  Barber, L.D. and Madrigal, J.A. (2006) Exploiting Beneficial Alloreactive T Cells. Vox Sanguinis, 91, 20-27.
https://doi.org/10.1111/j.1423-0410.2006.00775.x
[11]  Jacobsen, I.M. and Claesson, M.H. (1998) Veto Cell Suppression Mechanisms in the Prevention of Allograft Rejection. American Pathology, Microbiology and Immunology Society, 106, 345-353.
https://doi.org/10.1111/j.1699-0463.1998.tb01356.x
[12]  Pierce, G.E. (1990) Allogeneic versus Semiallogeneic F1 Bone Marrow Transplantation into Sublethally Irradiated MHC-Disparate Hosts. Effects on Mixed Lymphoid Chimerism, Skin Graft Tolerance, Host Survival, and Alloreactivity. Transplantation, 49, 138-144.
https://doi.org/10.1097/00007890-199001000-00031
[13]  Sykes, M., Sharabi, Y. and Sachs, D.H. (1988) Achieving Alloengraftment without Graft-versus-Host Disease: Approaches Using Mixed Allogeneic Bone Marrow Transplantation. Bone Marrow Transplantation, 3, 379-386.
[14]  Kuribayashi, K., Masuda, T. and Hanaoka, M. (1988) Lethal Graft-versus-Host Disease in Nude Mice I. Establishment of Model Systems. Transplantation, 46, 267-272.
https://doi.org/10.1097/00007890-198808000-00016
[15]  Nimmerjahn, A., Kirchhoff, F. and Helmchen, F. (2005) Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo. Science, 308, 1314-1318.
https://doi.org/10.1126/science.1110647
[16]  Kettenmann, H. (2007) The Brain’s Garbage Men. Nature, 446, 987-989.
https://doi.org/10.1038/nature05713
[17]  Yu, J., Kindy, M.S. and Gattoni-Celli, S. (2009) Semi-Allogeneic Vaccines and Tumor-Induced Immune Tolerance. Journal of Translational Medicine, 7, Article No. 3.
https://doi.org/10.1186/1479-5876-7-3
[18]  Lima, F.R.S., Kahn, S.A., Soletti, R.C., Biasoli, D., Alves, T., da Fonseca, A.C.C., et al. (2012) Glioblastoma: Therapeutic Challenges, What Lies Ahead. Biochimica et Biophysica—Acta Reviews on Cancer, 1826, 338-349.
https://doi.org/10.1016/j.bbcan.2012.05.004
[19]  Carvalho da Fonseca, A.C. and Badie, B. (2013) Microglia and Macrophages in Malignant Gliomas: Recent Discoveries and Implications for Promising Therapies. Clinical and Developmental Immunology, 2013, 1-5.
https://doi.org/10.1155/2013/264124
[20]  Zhang, Z.M., Yang, Z. and Zhang, Z. (2015) Distribution and Characterization of Tumor-Associated Macrophages/Microglia in Rat C6 Glioma. Oncology Letters, 10, 2442-2446.
https://doi.org/10.3892/ol.2015.3533
[21]  Tanaka, T., Murakami, K., Bando, Y. and Yoshida, S. (2015) Interferon Regulatory Factor 7 Participates in the M1-Like Microglial Polarization Switch. Glia, 63, 595-610.
https://doi.org/10.1002/glia.22770
[22]  Coniglio, S.J., Eugenin, E., Dobrenis, K., Stanley, E.R., West, B.L., Symons, M.H., et al. (2012) Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Molecular Medicine, 18, 519-527.
https://doi.org/10.2119/molmed.2011.00217
[23]  Markovic, D.S., Vinnakota, K., Chirasani, S., Synowitz, M., Raguet, H., Stock, K., et al. (2009) Gliomas Induce and Exploit Microglial MT1-MMP Expression for Tumor Expansion. Proceedings of the National Academy of Sciences, 106, 12530-12535.
https://doi.org/10.1073/pnas.0804273106
[24]  Pu, P., Zhang, Z., Kang, C., Jiang, R., Jia, Z., Wang, G., et al. (2009) Downregulation of Wnt2 and Β-Catenin by siRNA Suppresses Malignant Glioma Cell Growth. Cancer Gene Therapy, 16, 351-361.
https://doi.org/10.1038/cgt.2008.78
[25]  Wu, A., Wei, J., Kong, L., Wang, Y., Priebe, W., Qiao, W., et al. (2010) Glioma Cancer Stem Cells Induce Immunosuppressive Macrophages/Microglia. Neuro-Oncology, 12, 1113-1125.
https://doi.org/10.1093/neuonc/noq082
[26]  Hu, F., Ku, M.C., Markovic, D., Dzaye, O., Lehnardt, S., Synowitz, M., et al. (2014) Glioma-Associated Microglial MMP9 Expression Is Upregulated by TLR2 Signaling and Sensitive to Minocycline. International Journal of Cancer, 135, 2569-2578.
https://doi.org/10.1002/ijc.28908
[27]  Hu, F., a Dzaye, O.D., Hahn, A., Yu, Y., Scavetta, R.J., Dittmar, G., et al. (2015) Glioma-Derived Versican Promotes Tumor Expansion via Glioma-Associated Microglial/Macrophages Toll-Like Receptor 2 Signaling. Neuro-Oncology, 17, 200-210.
https://doi.org/10.1093/neuonc/nou324
[28]  Sallusto, F. and Lanzavecchia, A. (1994) Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-Stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor Alpha. The Journal of Experimental Medicine, 179, 1109-1118.
https://doi.org/10.1084/jem.179.4.1109
[29]  Amici, S.A., Dong, J. and Guerau-de-Arellano, M. (2017) Molecular Mechanisms Modulating the Phenotype of Macrophages and Microglia. Frontiers in Immunology, 8, Article 1520.
https://doi.org/10.3389/fimmu.2017.01520
[30]  Alloatti, A., Kotsias, F., Magalhaes, J.G. and Amigorena, S. (2016) Dendritic Cell Maturation and Cross-Presentation: Timing Matters. Immunological Reviews, 272, 97-108.
https://doi.org/10.1111/imr.12432
[31]  Jain, P., Neveu, B., Velot, L., Wu, L., Fradet, Y. and Pouliot, F. (2016) Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. Scientific Reports, 6, Article No. 33968.
https://doi.org/10.1038/srep33968
[32]  O’Keeffe, M., Mok, W.H. and Radford, K.J. (2015) Human Dendritic Cell Subsets and Function in Health and Disease. Cellular and Molecular Life Sciences, 72, 4309-4325.
https://doi.org/10.1007/s00018-015-2005-0
[33]  Pierce, G.E. and Watts, L.M. (1989) Effects of Thy-1+ Cell Depletion on the Capacity of Donor Lymphoid Cells to Induce Tolerance across An Entire MHC Disparity in Sublethally Irradiated Adult Hosts. Transplantation, 48, 289-295.
https://doi.org/10.1097/00007890-198908000-00021
[34]  Thurnher, M. (2007) Lipids in Dendritic Cell Biology: Messengers, Effectors, and Antigens. Journal of Leukocyte Biology, 81, 154-160.
https://doi.org/10.1189/jlb.0706438
[35]  Larmonier, N., Fraszczak, J., Lakomy, D., Bonnotte, B. and Katsanis, E. (2010) Killer Dendritic Cells and Their Potential for Cancer Immunotherapy. Cancer Immunology, Immunotherapy, 59, 1-11.
https://doi.org/10.1007/s00262-009-0736-1
[36]  Li, W., Holsinger, R.M.D., Kruse, C.A., Flügel, A. and Graeber, M.B. (2013) The Potential for Genetically Altered Microglia to Influence Glioma Treatment. CNS & Neurological Disorders—Drug Targets, 12, 750-762.
https://doi.org/10.2174/18715273113126660171
[37]  Gattoni-Celli, S. and Young, M.R.I. (2016) Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine. International Journal of Molecular Sciences, 17, Article 1465.
https://doi.org/10.3390/ijms17091465

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133